JavaScript has to be enabled to view this site. Learn how to enable JavaScript.

ICSI Icon

Lipid Management in Adults

This Guideline is Currently under Revision

Guideline Summary

Revision Date: November 2013
Thirteenth Edition

Scope and Target Population

This guideline describes the treatment of adults age 20 and older who are dyslipidemic.

Aims

  1. Increase the percentage of patients with:
    (a) established ASCVD: CHD, PAD or stroke presumed of atherosclerotic origin, or
    (b) whose 10-year risk for CHD > 10%, or
    (c) diabetes who are on a statin OR have LDL < 100 ml/dL within a 12-month period.
  2. Increase the percentage of patients with established ASCVD or 10-year CHD risk > 10% or diabetes and on lipid-lowering medication who receive regular follow-up care for lipid disorder.
  3. Increase the percentage of patients established ASCVD or 10-year CHD risk > 10% or diabetes and on lipid-lowering therapy who remain on the medication therapy.

Clinical Highlights

  • Initiate a statin with patients who have established ASCVD.
  • Establish lipid goals based on risk level.
  • Instruct patients on healthy lifestyle and adjunctive measures.
  • Patient adherence with recommended therapy should be reinforced during scheduled follow-up.

Additional Background

The guideline is a natural follow-up to the ICSI Preventive Services for Adults Guideline. Management of lipid disorder in adults is an area of practice variability among providers. The condition is relatively common in the adult population and treatment costs can be significant. The guideline incorporates recommendations from the National Cholesterol Education Program (NCEP-ATP III) and research studies which include: the Framingham Study, WOSCOPS, TexCAPS, 4S, Helsinki Heart Study, HITS Trial, The LIPID Study, and HERS.